• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 30, 2018

View Archived Issues

Financings

Esperite N.V., of Amsterdam, The Netherlands, which is focused on regenerative and precision medicine, said a 21st tranche of €300,000 has been issued as a private placement consisting of 30 convertible notes with a principal amount of €10,000 each, with 485,611 share subscription warrants attached. The financing was made under an agreement of up to €13 million that was signed with the European Select Growth Opportunities Fund in March last year. Read More

Appointments and advancements

Congenica Ltd., of Cambridge, U.K., appointed Wendy Britten chief financial officer, effective Sept. 1. Read More

Regulatory front

The FDA launched its new pilot program Wednesday to give participating drug and biologic companies additional opportunities to meet with agency staff to discuss the use of novel complex innovative trial designs.  Read More

Clinical data for Aug. 29, 2018

Read More

Other news to note

Hesperos Inc., of Orlando, Fla., received a phase I SBIR grant from the National Institute on Aging to help create a new multi-organ "human-on-a-chip" model that can realistically mimic the biology of Alzheimer's disease and the effects of potential new therapies. Read More

Invenra comes into its own, puts down stakes in bispecific landscape

You could say Invenra Inc. has been working toward bispecific antibodies for years. Founded in 2011, the University of Wisconsin-Madison spin-off launched with the aim of making antibody drug discovery more efficient, eventually developing a platform based on ultra-high-throughput technology capable of synthesizing hundreds of thousands of full-length antibodies using cell-free expression, with a screening platform that allows researchers to pinpoint those with the most promising biological activity.  Read More

New lymph node discovery may improve vaccines

Australian researchers have identified for the first time in decades a previously unknown immune system microstructure, which they have demonstrated to be responsible for immunological memory. Read More

Sophiris' choice: phase III as patient death resolved, topsalysin escapes blame

Back on track with topsalysin in prostate cancer (PC) after a patient died in the phase IIb trial, Sophiris Bio Inc. is taking aim at a pivotal push to verify encouraging data that have turned up so far. CEO Randall Woods told BioWorld that "most people didn't believe the drug was related to the death of the patient, but unlike in the legal system, where you're innocent until proven guilty, in this case you're guilty until you can prove otherwise." Read More

Want biosimilar competition? Patrol innovators' speech, Pfizer tells FDA

Pfizer Inc. is asking the FDA to become the speech police to protect the U.S.'s emerging biosimilar market from innovators' verbal assaults. Pfizer petitioned the agency to issue guidance spelling out what's inappropriate or would be considered misleading for the sponsors of reference biologics to say about biosimilars and interchangeables. Read More

'Adapt'ive strategy? Potential $735M deal broadens Emergent's product portfolio

Emergent Biosolutions Inc. positioned its pick-up of Adapt Pharma Ltd. as an opportunity to diversify and expand the company's presence in medical countermeasures and threats to public health by adding Adapt's flagship product, Narcan (naloxone HCI), developed by Lightlake Therapeutics Inc. and still the only nasal form of naloxone approved by the FDA for emergency treatment of known or suspected opioid overdose. (See BioWorld Today, Nov. 20, 2015.) Read More

Regulatory actions for Aug. 29, 2018

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe